{
  "extraction_metadata": {
    "timestamp": "2025-09-29T11:54:10.221682",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 9,
    "total_picos": 17
  },
  "picos_by_country": {
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "PICOs": [
        {
          "Population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "sotorasib",
          "Outcomes": "overall response rate, progression-free survival, diarrhoea, alanine aminotransferase increase, aspartate aminotransferase increase, neutropenia, fatigue, febrile neutropenia"
        },
        {
          "Population": "patients with KRAS G12C and performance status 0-2 and previously treated with platinum-based chemotherapy and immunotherapy (where applicable)",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "overall response rate, progression-free survival, diarrhoea, alanine aminotransferase increase, aspartate aminotransferase increase, neutropenia, fatigue, febrile neutropenia"
        },
        {
          "Population": "patients with oncogene-driven NSCLC treated with immunotherapy alone",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "immunotherapy monotherapy",
          "Outcomes": "overall response rate, progression-free survival, diarrhoea, alanine aminotransferase increase, aspartate aminotransferase increase, neutropenia, fatigue, febrile neutropenia"
        },
        {
          "Population": "patients with advanced NSCLC and KRAS G12C mutation previously treated with platinum-based chemotherapy and immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall response rate, progression-free survival, diarrhoea, alanine aminotransferase increase, aspartate aminotransferase increase, neutropenia, fatigue, febrile neutropenia"
        }
      ],
      "ChunksUsed": 16,
      "ContextTokens": 3464
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "PICOs": [
        {
          "Population": "metastatic, p. G12C mutant KRAS NSCLL patients progressing following prior platinum-based chemotherapies",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": "PD-L1 positivity (Tumor Proportional Score), molecular alterations (next-generation sequencing), EGFR exons 18, 19, 20 and 21 mutations, ALK rearrangement, ROS1 rearrangement, RET rearrangement, NTRK rearrangement, MET 14 skipping, BRAF V600 point mutations, KRAS G12C mutation, PD-L1 expression (immunohistochemistry)"
        }
      ],
      "ChunksUsed": 4,
      "ContextTokens": 919
    },
    "EL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EL",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "progression-free survival, overall survival"
        }
      ],
      "ChunksUsed": 1,
      "ContextTokens": 331
    },
    "NL": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "NL",
      "PICOs": [
        {
          "Population": "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        },
        {
          "Population": "patients with non–small-cell lung cancer stage IIIB/IV and a KRAS G12C mutation",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "chemotherapy",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        },
        {
          "Population": "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "gemcitabine",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        },
        {
          "Population": "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        },
        {
          "Population": "metastatic NSCLC harboring a KRAS mutation, who received prior chemotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "pemetrexed",
          "Outcomes": "progression free survival, quality of life, overall survival, objective response rate, adverse events"
        }
      ],
      "ChunksUsed": 10,
      "ContextTokens": 2131
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "PICOs": [
        {
          "Population": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "",
          "Outcomes": "symptom control, preservation of quality of life, prolonged survival"
        }
      ],
      "ChunksUsed": 7,
      "ContextTokens": 1539
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "PICOs": [
        {
          "Population": "adult patients with advanced non-small cell adagrasib bronchial cancer (ASBC) with KRAS G12C mutation, whose disease has progressed after at least one prior systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "adagrasib",
          "Outcomes": "serious side effects on the skin"
        }
      ],
      "ChunksUsed": 14,
      "ContextTokens": 3364
    },
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "PICOs": [
        {
          "Population": "Patients with Stage IV NSCLC with a KRAS-G12C mutation and failure of at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "Sotorasib",
          "Outcomes": "overall survival, response rate, progression-free survival, Karnofsky performance status, ECOG performance status"
        }
      ],
      "ChunksUsed": 4,
      "ContextTokens": 692
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "PICOs": [
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "overall survival, progression-free survival, objective response rate (RECIST 1.1), health-related quality of life, physical benefits, psychological benefits"
        },
        {
          "Population": "KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed on, or who cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel plus nintedanib",
          "Outcomes": "overall survival, progression-free survival, objective response rate (RECIST 1.1), health-related quality of life, physical benefits, psychological benefits"
        }
      ],
      "ChunksUsed": 32,
      "ContextTokens": 6344
    },
    "AT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "AT",
      "PICOs": [
        {
          "Population": "patients with advanced NSCLC with a KRAS-G12C mutation that has progressed after at least one systemic therapy",
          "Intervention": "Medicine X (under assessment)",
          "Comparator": "docetaxel",
          "Outcomes": "response rate, progression-free survival, diarrhoea, dilation, nausea, transaminase increase, creatinine increase, QTc time prolongation"
        }
      ],
      "ChunksUsed": 12,
      "ContextTokens": 2586
    }
  }
}